References
- Ueki Y, Yamasaki Y, Kanamoto T, Kawazu T, Yano M, Matsumoto K, et al. Evaluation of filtration leukocytapheresis for use in the treatment of patients with rheumatoid arthritis. Ftheumatology 2000;39:165–71.
- Hidaka T, Suzuki K, Matsuki Y, Takamizawa-Matsumoto M, Kataharada K, Ishizuka T, et al. Filtration leukocytapheresis thera-py in rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1999;42:431–7.
- Kempe K, Tsuda H, Yang K, Yamaji K, Kanai Y, Hashimoto H. Filtration leukocytapheresis therapy in the treatment of rheumatoid arthritis patients resistant to or failed with methotrexate. Ther Apher Dial 2004;8:197–205.
- Buch MH, Conaghan PG, Quin MA, Bingham SJ, Veale D, Emery P. True infliximab resistance in rheumatoid arthritis: a role for lym-photoxin a? Ann Rheum Dis 2004;63:1344–6.
- Martinez A, Safi& M, Bonilla G, Pascual-Salcedo D, Fernandez-Arquero M, Miguel S, et al. Association of the major histocompati-bility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum 2004;50:1077–82.
- St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, et al. The relationship of serum infliximab concentra-tions to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1451–9.
- Van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treat-ment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STUFtE registry showing that switching tumor necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003;62:1195–8.
- Izumi Y, Tominaga M, Iwanaga N, Huang M, Tanaka F, Aratake K, et al. Twenty-four-week follow-up examination of a leukocy-tapheresis therapy in rheumatoid arthritis. Mod Ftheumatol 2006; 16:20–3.